Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Last week in January

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Jan 24, 2021 10:11pm

233 Views

Post# 32372743

RE:RE:RE:RE:Last week in January

There’s your mistake, Katz. It’s not a play, it’s a long term investment.

And yes, while he seems like a nice guy in interviews, Dan is disappointing as a CEO. But unfortunately he’s not going anywhere any time soon. He’s best friends with JLW

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks